Skip to main content
. 2011 Jul;338(1):114–124. doi: 10.1124/jpet.111.180257

Fig. 7.

Fig. 7.

Antihyperalgesic effects of PF-04457845 in the CFA model of inflammatory pain in rats. A, PF-04457845 at 0.003 to 10 mg/kg p.o. produces a reduction of mechanical allodynia (hyperalgesia) (black bars). The effect of the nonsteroidal anti-inflammatory drug naproxen (10 mg/kg p.o., hatched bar) is shown for comparison. PWTs were measured at 4 h after drug treatment and were significantly different for PF-04457845 (0.1–10 mg/kg) and naproxen compared with vehicle-treated groups. ***, p < 0.001; n = 8 rats/group. B, C, and D, PF-04457845-treated rats at 0.1 to 10 mg/kg show near-complete inhibition of FAAH activity (B), elevated AEA levels in brain tissue and blood leukocytes/plasma (C), and elevated PEA/OEA levels in brain tissue (D). All FAAH activity and NAE measurements were determined at 4 h after drug treatment and were significantly different between PF-0457845- and vehicle-treated groups (p < 0.001 for FAAH activity; p < 0.01 for NAEs; n = 3 rats/group). E, brain and plasma levels of PF-04457845 measured at 4 h after drug treatment. n = 3 rats/group. All data are expressed as means ± S.E.M.